Cancer research and treatment has evolved considerably over recent years, and one of the most promising modalities to emerge is immuno-oncology.
Arguably one of the greatest breakthroughs in modern medicine, immuno-oncology essentially unlocks the breaks on the body’s natural ability to attack and fight off cancer.
Immuno-oncology therapeutics help to reprogram the immune system so that it recognizes and destroys cancer cells, which under normal circumstances may be able to evade an immune system attack.
Pharmaceutical companies are pursuing several types of immuno-oncology products, including checkpoint inhibitors, tumor necrosis factor receptor agonists, adoptive T-cell therapies such as chimeric antigen receptor T-cell (CAR-T) technology, tumor-infiltrating lymphocytes, and vaccines.
As of July 2019, there are 25 immuno-oncology therapies (including monotherapies and combinations with chemotherapies or other products, but excluding biosimilars) launched throughout the world for a wide range of solid and hematological tumors.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.